Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives $17.56 Consensus PT from Analysts

Alphatec Holdings, Inc. (NASDAQ:ATEC) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $17.56.

ATEC has been the topic of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. Barclays lifted their price objective on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Finally, Needham & Company LLC lifted their price objective on shares of Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a research note on Monday, January 13th.

Alphatec Stock Performance

Shares of ATEC opened at $10.61 on Monday. The firm’s 50 day moving average is $10.48 and its 200-day moving average is $8.24. The stock has a market capitalization of $1.50 billion, a P/E ratio of -8.29 and a beta of 1.43. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec has a 12-month low of $4.88 and a 12-month high of $15.69.

Insiders Place Their Bets

In related news, CEO Patrick Miles sold 6,687 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $12.00, for a total transaction of $80,244.00. Following the completion of the sale, the chief executive officer now directly owns 5,501,715 shares in the company, valued at approximately $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Sponsel sold 58,283 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $10.71, for a total transaction of $624,210.93. Following the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 222,376 shares of company stock worth $2,557,148 over the last ninety days. 22.80% of the stock is currently owned by company insiders.

Institutional Trading of Alphatec

Institutional investors have recently made changes to their positions in the stock. R Squared Ltd acquired a new stake in shares of Alphatec during the fourth quarter worth approximately $29,000. Comerica Bank boosted its holdings in shares of Alphatec by 66.8% during the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 1,248 shares during the period. Nisa Investment Advisors LLC boosted its holdings in shares of Alphatec by 973.3% during the fourth quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock worth $43,000 after purchasing an additional 4,234 shares during the period. Quarry LP boosted its holdings in shares of Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after purchasing an additional 2,375 shares during the period. Finally, Newton One Investments LLC acquired a new stake in Alphatec in the fourth quarter valued at approximately $50,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.